Drug
Letrozole 2.5Mg Tablet
Letrozole 2.5Mg Tablet is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_4
1
25%
Ph not_applicable
1
25%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (50.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
completed250%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle
NCT05166668
unknownphase_4
The Outcomes of ICSI Cycles With and Without Letrozole
NCT04159649
unknownphase_2
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
NCT03024580
completedphase_2
Neoadjuvant Endocrine Therapy in Breast Cancer
NCT03397537
Clinical Trials (4)
Showing 4 of 4 trials
NCT05166668Not Applicable
Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle
NCT04159649Phase 4
The Outcomes of ICSI Cycles With and Without Letrozole
NCT03024580Phase 2
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
NCT03397537Phase 2
Neoadjuvant Endocrine Therapy in Breast Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4